Butterworth C J, Baxter A M, Shaw M J, Bradnock G
Specialist Registrar in Restorative Dentistry, Birmingham Dental Hospital and School, St Chad's Queensway.
Br Dent J. 2001 Jan 27;190(2):93-6. doi: 10.1038/sj.bdj.4800892.
To assess the activity of consultants in restorative dentistry in the United Kingdom in the provision of osseointegrated dental implants within the National Health Service Hospital service and to evaluate their attitudes concerning the relevant medical and oral factors considered in patient selection for implant treatment.
DESIGN/SETTING: Anonymous postal questionnaire in the United Kingdom.
Consultants in restorative dentistry.
Out of the sample of 145, 109 consultants (75%) completed the questionnaire in 1999. 54 of the 109 consultants (49.5%) are involved in the provision of osseointegrated implant treatment, treating an average of 29 cases/year (range 2-150). However, over one third of the respondents treated 10 or less cases/year. 89% worked with oral surgeons as an implant team. 68% used Branemark (Nobel Biocare) implants as their main system. The majority of consultants felt that smoking, psychoses and previous irradiation were the most important medical factors that contra-indicated implant retained restorations whilst untreated periodontitis, poor oral hygiene and uncontrolled caries were the most important oral contra-indications. Many centres were experiencing significant problems with the funding of implant treatment with one centre receiving no funding. The implications for patient care and specialist training are discussed.
There is a marked variation in the number of patients treated with endosseous dental implants within the United Kingdom National Health Service hospitals. Many consultants treat 10 or fewer patients each year. In the main, there is agreement about the factors that contra-indicate implant treatment; these are in line with national guidelines.
评估英国国民医疗服务体系医院服务中修复牙科顾问在提供骨结合牙种植体方面的活动,并评估他们对种植治疗患者选择中所考虑的相关医学和口腔因素的态度。
设计/地点:在英国进行匿名邮寄问卷调查。
修复牙科顾问。
在145名样本中,109名顾问(75%)于1999年完成了问卷。109名顾问中有54名(49.5%)参与提供骨结合种植治疗,平均每年治疗29例(范围为2 - 150例)。然而,超过三分之一的受访者每年治疗10例或更少病例。89%作为种植团队与口腔外科医生合作。68%使用Branemark(诺贝尔生物科技)种植体作为其主要系统。大多数顾问认为吸烟、精神病和既往放疗是种植修复的最重要医学禁忌因素,而未经治疗的牙周炎、口腔卫生差和龋齿未控制是最重要的口腔禁忌证。许多中心在种植治疗资金方面遇到重大问题,有一个中心没有获得资金。讨论了对患者护理和专科培训的影响。
在英国国民医疗服务体系医院中接受骨内牙种植体治疗的患者数量存在显著差异。许多顾问每年治疗10名或更少患者。总体而言,对于种植治疗禁忌因素存在共识;这些与国家指南一致。